Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 412

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 412
---
171 |           16,573 |           19,273 |
| Cash and cash equivalents                                                     |                            -7,441 |               |                                        |              -7,441 |           -8,710 |          -12,736 |
| Interest rate and currency derivativesused to manage cash and cashequivalents |                                76 |               |                                        |                  76 |              -28 |              -45 |
| Net debt                                                                      |                             8,772 |            34 |                                      — |               8,806 |            7,835 |            6,492 |

| SANOFIFORM 20-F2024 | F-57 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

a) Principal financing transactions during the year The table below shows the movement in total debt during the period:

|                                                          |                  | Cash flows fromfinancing activities |               |                   |                    Non-cash items |                                            |               |                  |
| (€ million)                                              | December 31,2023 |                          Repayments | Newborrowings | Othercashflows(a) | Currencytranslationdifferences(b) | Reclassificationfrom non-currentto current | Otheritems(c) | December 31,2024 |
| Long-term debt                                           |           14,347 |                                 -67 | —             |                 — |                                63 |                                     -2,599 |            47 |           11,791 |
| Short-term debt andcurrent portion oflong-term debt      |            2,045 |                                -605 | —             |               242 |                                 9 |                                      2,599 |           -81 |            4,209 |
| Interest rate andcurrency derivativesused to manage debt |              139 |                                   — | —             |              -132 |                               146 |                                          — |           -16 |              137 |
| Total debt                                               |           16,531 |                                -672 | —             |               110 |                               218 |                                          — |           -50 |           16,137 |

(a)These amounts mainly comprise € 262million related to the US commercial paper program.

(b) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.

(c) These amounts mainly comprise changes in accrued interest balances, and fair value adjustments.

Sanofi did not carry out any bond issues in 2024. One bond issue was redeemed in 2024: